Efficacy and Safety of Sugammadex versus Neostigmine in Reversing Neuromuscular Blockade in Morbidly Obese Adult Patients
Anesthesia Essays & Researches · 2021-01 · 15 (1) · 111-118
DOI: 10.4103/aer.aer_79_21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anesthesia Essays & Researches, 2021-01. Verfasst von Yamini Subramani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia and Perioperative Medicine, London Health Sciences Centre and St Joseph Health Care, Schulich School of Medicine and Dentist…. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Context
Sugammadex is known to reverse neuromuscular blockade (NMB) more rapidly and reliably than neostigmine. However, data remain limited in bariatric patients. In this review, we systematically evaluated the efficacy and safety of sugammadex versus neostigmine in reversing NMB in morbidly obese (MO) patients undergoing bariatric surgery.
Aims
Our primary objective was to determine the recovery time from drug administration to a train-of-four (TOF) ratio >0.9 from a moderate or deep NMB. Settings and Design: This systematic review and meta-analysis (SR and MA) was conducted in accordance with the Preferred Items for SRs and MAs guidelines. Subjects and Methods: A systematic search was conducted within multiple databases for studies that compared sugammadex and neostigmine in MO patients. Statistical Analysis Used: We reported data as mean difference (MD) or odds ratios (OR) and corresponding 95% confidence interval (CI) using random-effects models. A two-sided P < 0.05 was considered statistically significant.
Results
Seven studies with 386 participants met the inclusion criteria. Sugammadex significantly reduced the time of reversal of moderate NMB-to-TOF ratio >0.9 compared to neostigmine, with a mean time of 2.5 min (standard deviation [SD] 1.25) versus 18.2 min (SD 17.6), respectively (MD: −14.52; 95% CI: −20.08, −8.96; P < 0.00001; I 2 = 96%). The number of patients who had composite adverse events was significantly lower with sugammadex (21.2% of patients) compared to neostigmine (52.5% of patients) (OR: 0.15; 95% CI: 0.07–0.32; P < 0.00001; I 2 = 0%).
Conclusions
Sugammadex reverses NMB more rapidly with fewer adverse events than neostigmine in MO patients undergoing bariatric surgery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesia and Perioperative Medicine, London Health Sciences Centre and St Joseph Health Care, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
- Schulich school of Medicine and Dentistry, Western University, London, Ontario, Canada.
Zitieren
APA
Subramani, Y., Querney, J., He, S., Nagappa, M., Yang, H., & Fayad, A. (2021). Efficacy and Safety of Sugammadex versus Neostigmine in Reversing Neuromuscular Blockade in Morbidly Obese Adult Patients. Anesthesia Essays & Researches, 15(1), 111-118. https://doi.org/10.4103/aer.aer_79_21
Vancouver
Subramani Y, Querney J, He S, Nagappa M, Yang H, Fayad A. Efficacy and Safety of Sugammadex versus Neostigmine in Reversing Neuromuscular Blockade in Morbidly Obese Adult Patients. Anesthesia Essays & Researches. 2021;15(1):111-118. doi:10.4103/aer.aer_79_21
BibTeX
@article{Subramani2021,
author = {Subramani, Yamini and Querney, Jill and He, Susan and Nagappa, Mahesh and Yang, Homer and Fayad, Ashraf},
title = {Efficacy and Safety of Sugammadex versus Neostigmine in Reversing Neuromuscular Blockade in Morbidly Obese Adult Patients},
journal = {Anesthesia Essays & Researches},
year = {2021},
volume = {15},
number = {1},
pages = {111--118},
doi = {10.4103/aer.aer_79_21}
}
EUVIMED